ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2021
Molecular Imaging of Very Late Antigen-4 in Acute Lung Injury.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 15 citations in OpenAlex.
- Fibrotic Disease: from Signaling Pathways and Biomarkers to Molecular Imaging.Molecular imaging and biology · 2025Review
- Integrins and pulmonary fibrosis: Pathogenic roles and therapeutic opportunities.Biomolecules & biomedicine · 2025Review
- Consumption of Endogenous Caspase-3 Activates Molecular Theranostic Nanoplatform against Inflammation-Induced Profibrotic Positive Feedback in Pulmonary Fibrosis.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- CD45-targeted PET enables the visualization of inflammatory conditions.American journal of nuclear medicine and molecular imaging · 2025Article
- Adhesion molecule-targeted magnetic particle imaging nanoprobe for visualization of inflammation in acute lung injury.European journal of nuclear medicine and molecular imaging · 2024Article
- Molecular Imaging of Fibrosis in Benign Diseases: An Overview of the State of the Art.Pharmaceuticals (Basel, Switzerland) · 2024Review
- 2-deoxy-2-[Molecular imaging and biology · 2023Article
- Targeted imaging of very late antigen-4 for noninvasive assessment of lung inflammation-fibrosis axis.EJNMMI research · 2023Article
- Novel STING-targeted PET radiotracer for alert and therapeutic evaluation of acute lung injury.Acta pharmaceutica Sinica. B · 2023Article
- Molecular imaging of chemokine-like receptor 1 (CMKLR1) in experimental acute lung injury.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Visualizing γδ T cells by very late antigen-4-targeted positron emission tomography.European journal of nuclear medicine and molecular imaging · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Inflammation plays a central role in the pathogenesis of acute lung injury (ALI) during both the acute pneumonitis stage and progression into the chronic fibroproliferative phase, leading to pulmonary fibrosis. Currently, there is an unmet clinical and research need for noninvasive ways to monitor lung inflammation through targeting of immunoregulatory pathways contributing to ALI pathogenesis. In this study, we evaluated the role of targeted imaging of very late antigen-4 (VLA-4), as a key integrin mediating the adhesion and recruitment of immune cells to inflamed tissues, in quantifying lung inflammation in a mouse model of lipopolysaccharide-induced ALI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.